Susceptibility Profiles of Candida Species from Diverse Clinical Samples: A Tertiary Hospital Analysis
Keywords:
Candida species, antifungal susceptibility, tertiary care hospital, non-albicans Candida, fluconazole resistanceAbstract
Introduction: Candida species have emerged as significant opportunistic pathogens in healthcare settings, particularly in tertiary care hospitals. This study aimed to investigate the antibiotic sensitivity patterns of Candida species isolated from various clinical specimens in a tertiary care hospital, providing crucial data for optimizing antifungal therapy and understanding local Candida epidemiology.
Methods: A prospective, observational study was conducted over six months in a 1000-bed tertiary care hospital. Consecutive sampling was employed to collect 300 Candida isolates from various clinical specimens and Vitek -2 system was used to identify Candida species. Antifungal susceptibility testing was conducted using the broth microdilution method following CLSI guidelines.
Results: Candida albicans were the predominant species (45%), followed by C. glabrata (20%), C. tropicalis (15%), and C. parapsilosis (10%). Urine samples yielded the highest number of isolates (30%), followed by blood (25%) and respiratory specimens (20%). Amphotericin B demonstrated 100% susceptibility across all species. Fluconazole showed variable activity, with reduced susceptibility in C. glabrata (65% susceptible). Echinocandins showed excellent activity against most species. The highest resistance rate was observed for fluconazole (15%), followed by voriconazole (6%). The Intensive Care Unit accounted for 35% of all isolates.
Conclusion: The study highlights the significant presence of non-albicans Candida species and variable antifungal susceptibility patterns. These findings emphasize the importance of species-level identification, routine antifungal susceptibility testing, and judicious use of antifungal agents. Implementation of targeted antifungal strategies and enhanced surveillance in high-risk areas is crucial for optimizing management of Candida infections in tertiary care settings.
References
Arendrup, M. C. (2004). Update on antifungal resistance in Aspergillus and Candida. Clinical Microbiology and Infection, 20, 42-48.
Castanheira, M., Messer, S. A., Rhomberg, P. R., & Pfaller, M. A. (2010). Antifungal susceptibility patterns of a global collection of fungal isolates: Results of the SENTRY Antifungal Surveillance Program (2013). Diagnostic Microbiology and Infectious Disease, 85(2), 200-204.
Chowdhary, A., Sharma, C., & Meis, J. F. (2007). Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathogens, 13(5), e1006290.
Cleveland, A. A., Harrison, L. H., Farley, M. M., Hollick, R., Stein, B., Chiller, T. M., ... & Park, B. J. (2005). Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: Results from population-based surveillance. PLoS One, 10(3), e0120452.
Colombo, A. L., Guimarães, T., Sukienik, T., Pasqualotto, A. C., Andreotti, R., Queiroz-Telles, F., ... & Nucci, M. (2014). Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Medicine, 40(10), 1489-1498.
Hou, X., Lee, A., Jimenez-Ortigosa, C., Kordalewska, M., Perlin, D. S., & Zhao, Y. (2008). Rapid detection of ERG11-associated azole resistance and FKS-associated echinocandin resistance in Candida auris. Antimicrobial Agents and Chemotherapy, 62(9), e01811-18.
Kauffman, C. A., Vazquez, J. A., Sobel, J. D., Gallis, H. A., McKinsey, D. S., Karchmer, A. W., ... & Dismukes, W. E. (2011). Prospective multicenter surveillance study of funguria in hospitalized patients. Clinical Infectious Diseases, 30(1), 14-18.
Kullberg, B. J., & Arendrup, M. C. (2005). Invasive candidiasis. New England Journal of Medicine, 373(15), 1445-1456.
Lockhart, S. R. (2010). Current epidemiology of Candida infection. Clinical Microbiology Newsletter, 36(17), 131-136.
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., ... & Berkow, E. L. (2007). Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clinical Infectious Diseases, 64(2), 134-140.
Lortholary, O., Renaudat, C., Sitbon, K., Madec, Y., Denoeud-Ndam, L., Wolff, M., ... & French Mycosis Study Group. (2007). Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Medicine, 40(9), 1303-1312.
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., ... & Sobel, J. D. (2008). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1-e50.
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2007). The global problem of antifungal resistance: prevalence, mechanisms, and management. The Lancet Infectious Diseases, 17(12), e383-e392.
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2010). Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016. Open Forum Infectious Diseases, 6(Supplement_1), S79-S94.
Wisplinghoff, H., Ebbers, J., Geurtz, L., Stefanik, D., Major, Y., Edmond, M. B., ... & Seifert, H. (2010). Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. International Journal of Antimicrobial Agents, 43(1), 78-81.
Arendrup, M. C., & Patterson, T. F. (2004). Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. The Journal of Infectious Diseases, 216(suppl_3), S445-S451.
Guinea, J. (2004). Global trends in the distribution of Candida species causing candidemia. Clinical Microbiology and Infection, 20, 5-10.
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2008). Changes in the epidemiological landscape of invasive candidiasis. Journal of Antimicrobial Chemotherapy, 73(suppl_1), i4-i13.
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2009). Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016. Open Forum Infectious Diseases, 6(Supplement_1), S79-S94.
Vallabhaneni, S., Cleveland, A. A., Farley, M. M., Harrison, L. H., Schaffner, W., Beldavs, Z. G., ... & Jackson, B. R. (2005). Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008–2014. Open Forum Infectious Diseases, 2(4), ofv163.
